Our Healthcare News

Elusys Therapeutics Receives First Delivery Order from US Government for Anthim

PINE BROOK, New Jersey – Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded its first delivery order under a procurement contract for Anthim…  

Nov 12 2015

Revance Reports Positive Six-Month Duration in BELMONT Study

NEWARK, California—(GLOBE NEWSWIRE)—Revance Therapeutics, Inc. (NASDAQ:RVNC), announced positive 24-week results today from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing…  

Oct 29 2015

Molecular Partners Wins European Biotechnica Award 2015

ZURICH, Switzerland—Molecular Partners AG (MOLN) announced today that it has been honored with the EUROPEAN BIOTECHNICA AWARD 2015. The award honors one company that has…  

Oct 07 2015

Elusys Awarded Additional $16 Million To Complete Development of Lyophilized Form of Anthim

PINE BROOK, New Jersey—Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded $16 million of additional funding from the U.S. Government to further advance…  

Oct 06 2015

FDA Accepts NDA for Abilify with Ingestible Sensor

—Amanda Pedersen, Senior Staff Writer, Medical Device Daily, September 15th, 2015

Digital technology has advanced to the point of allowing pharmaceutical companies to make drugs…  

Sep 15 2015

Essex Woodlands Fund IX Acquires Significant Position in AxoGen, Inc.

ALACHUA, Florida—AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has sold 4,861,111 registered shares of its…  

Aug 27 2015

Catalyst Biosciences Completes Merger with Targacept

SOUTH SAN FRANCISCO, California—(GLOBE NEWSWIRE)—Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, today…  

Aug 20 2015

Entellus Medical Announces Collaboration with Fiagon

PLYMOUTH, Minnesota—Entellus Medical, Inc. (“Entellus Medical” or the “Company”) (NASDAQ: ENTL), a medical technology company focused on the design, development and commercialization of products for…  

Aug 10 2015

Corium Prices Follow-On Offering of Common Stock

MENLO PARK, California (GLOBE NEWSWIRE)—Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced…  

Aug 05 2015